May 24, 2012 —Advanced Cardiac Therapeutics Inc., a developer of temperature-sensing cardiac ablation systems, today announced results of several studies related to the company’s Tempasure cardiac ablation catheter. The Tempasure system is designed to improve clinical outcomes with a novel microwave radiometry technology that allows the electrophysiologist to measure the temperature of cardiac tissue during the ablation procedure, providing real-time information that enables proper energy delivery and lesion control. Presentations took place at the Heart Rhythm Society's 33rd Annual Scientific Sessions in Boston.

May 24, 2012 -- nContact Inc., a provider of  epicardial ablation devices, announced that new long-term physician data demonstrated promising clinical outcomes for the multidisciplinary Convergent Procedure in the treatment of persistent atrial fibrillation (AF), with more than 80% of patients remaining in sinus rhythm at a minimum of 12 months follow-up. The data was presented by physicians at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, May 9-12 in Boston.

May 24, 2012 — Research led by Christiana Care Health System's Andrew Doorey, M.D., has found that a small number of patients mistakenly undergo bypass surgery after diagnostic angiography.

May 24, 2012 — Volcano Corp. provided an overview of data from multiple ground-breaking clinical trials presented last week at the EuroPCR conference, a key international cardiology meeting held in Paris.

May 23, 2012 - TriReme Medical Inc. announced approval by the U.S. Food and Drug Administration (FDA) of the Glider PTCA Catheter, indicated for treating the stenotic portion of coronary arteries or bypass grafts to improve myocardial perfusion. Glider is the only torqueable PTCA balloon catheter. Combined with its state of the art tip technology, Glider is designed to perform, even in the most challenging conditions. It is also available in an ultra-short balloon length of 4 mm designed for focal lesions.

May 23, 2012 — Edwards Lifesciences Corp. announced that data from its post-approval study involving 94 European centers performing transcatheter aortic valve replacement (TAVR) demonstrated positive outcomes for high-risk patients treated with the Edwards Sapien XT transcatheter heart valve. These data document the outcomes of 2,706 consecutively enrolled patients, representing more than 20 percent of the total patients treated with commercially available Sapien XT valves during the time period of this study. These data were presented today at EuroPCR 2012.

May 23, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that the introduction of multiple, new generic versions of clopidogrel into the U.S. market has led to increased interest in platelet reactivity testing. In addition to increased field interest, Accumetrics reports a 40 percent jump in traffic to its VerifyNow website.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now